Previous close | 1.5240 |
Open | 1.5280 |
Bid | 1.5020 x 0 |
Ask | 1.5480 x 0 |
Day's range | 1.5120 - 1.5560 |
52-week range | 1.4100 - 1.9480 |
Volume | |
Avg. volume | 154,968 |
Market cap | 417.701M |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | 77.40 |
EPS (TTM) | 0.0200 |
Earnings date | 26 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
STOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented a positive safety data from the first part of its clinical Phase 1b/2 study of golexanolone in patients with Primary Biliary Cholangitis, PBC. The second part of the study, which will now be initiated, aims to evaluate the preliminary efficacy of the drug candidate and further study its safety and tolerability profile. Top-line results
STOCKHOLM, SWEDEN – March 22, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces publication of its Annual Report 2023. The report is now available to download at www.karolinskadevelopment.com For further information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Hans-Christoffer “HC” Toll, CFO, Karolinska Development AB Phone: +46 70 717 00 41, e-mail: hc.toll@karolinskadevelopment.com
STOCKHOLM, SWEDEN, March 14, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has received FDA approval of the company’s IND application for the drug candidate APR-1051. Aprea has also secured funding up to USD 34 million through a financing round led by Sphera Healthcare. With the approval and financing in place, the company will be able to start the first clinical study with APR-1051. The American Food and Drug Administration (FDA